Skip to content

Clinical trials

Leukemia trials in Canada

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia Country / region: Canada Clear all

178 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200010
20014
20027
20032
20046
20058
20064
200711
20087
20097
20104
20115
20128
20135
20148
201510
20166
20177
20182
20195
20204
20213
20228
20232
20242
20251
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed116
Terminated25
Active, not recruiting13
Recruiting12
Unknown status10
No longer available1
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Children's Oncology Group40
Novartis Pharmaceuticals11
University Health Network, Toronto11
Bristol-Myers Squibb8
Celgene5
AstraZeneca4
Daiichi Sankyo4
NCIC Clinical Trials Group4
National Cancer Institute (NCI)4
Therapeutic Advances in Childhood Leukemia Consortium4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia178
Leukemia, Myeloid, Acute52
Precursor Cell Lymphoblastic Leukemia-Lymphoma49
Lymphoma32
Recurrence30
Myelodysplastic Syndromes21
Neoplasms17
Leukemia, Lymphocytic, Chronic, B-Cell16
Burkitt Lymphoma15
Leukemia, Myelogenous, Chronic, BCR-ABL Positive14

Trials

Showing 51 to 75 of 178. Each trial links to its page on Pharma Observatory.

78 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.